series-b
Stage
1
Investors
About
Elegen develops a proprietary cell-free DNA synthesis platform called ENFINIA™, which uses microfluidics, AI, and robotics to produce long, high-quality, clonal linear DNA rapidly and cost-effectively without cloning or cells.
Explore Elegen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.